Skip to main content

Rifaximin News

ACG: Fewer Overt Hepatic Encephalopathy Episodes Seen With Rifaximin

MONDAY, Oct. 28, 2024 – For patients with a history of overt hepatic encephalopathy (OHE), rifaximin monotherapy (MT) results in significantly fewer OHE episodes than lactulose (LAC) MT, according...

FDA Approves Xifaxan (rifaximin) for the Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea)

LAVAL, Quebec, May 27, 2015 /PRNewswire/ – Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received...

FDA Approves New Use of Xifaxan for Patients with Liver Disease

SILVER SPRING, Md., March 24 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved the use of Xifaxan for reduction in the risk of the recurrence of overt hepatic...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Irritable Bowel Syndrome, Crohn's Disease, Diarrhea

Related drug support groups

Xifaxan

Rifaximin patient information at Drugs.com